Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

被引：0
|
作者：
Chay, J. [1 ]
Su, R. [1 ]
Tung, J. Y. M. [2 ]
Aslim, E. J. [2 ]
Wong, C. [3 ]
Swan, G.
Chua, W. J. [4 ]
Ho, S. S. H. [2 ]
Finkelstein, E. A. [1 ]
机构：
[1] Duke NUS Med Sch, Hlth Serv & Syst Res, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Urol, Singapore, Singapore
[3] Boston Sci, Asia Pacific, Hlth Econ & Market Access, Singapore, Singapore
[4] Natl Univ Singapore Hosp, Dept Urol, Singapore, Singapore
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0034
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
    Chay, Junxing
    Tung, Joshua Yi Min
    Su, Rebecca Jade
    Aslim, Edwin Jonathan
    Wong, Callix
    Swan, Georgia
    Chua, Wei Jin
    Ho, Henry Sun Sien
    Finkelstein, Eric Andrew
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1269 - 1277
  • [2] Cost-effectiveness analysis of benign prostatic hyperplasia (BPH)treatments
    DiSantostefano, RL
    Biddle, AK
    Lavelle, JP
    JOURNAL OF UROLOGY, 2005, 173 (04): : 8 - 8
  • [3] Cost-effectiveness analysis of benign prostatic hyperplasia (BPH) treatments
    DiSantostefano, R
    Biddle, A
    Lavelle, J
    VALUE IN HEALTH, 2005, 8 (03) : 301 - 302
  • [4] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE PHARMACOLOGICAL TREATMENTS OF ACROMEGALY IN SPAIN
    Peral, C.
    Cordido, F.
    Gimeno, V
    Sanchez-Cenizo, L.
    Mir, N.
    Parrondo, J.
    VALUE IN HEALTH, 2017, 20 (09) : A557 - A558
  • [5] Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
    Chughtai, Bilal
    Rojanasarot, Sirikan
    Neeser, Kurt
    Gultyaev, Dmitry
    Amorosi, Stacey L.
    Shore, Neal D.
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2021, 8 (01): : 42 - 50
  • [6] Cost-effectiveness of dutasteride in the treatment of benign prostatic hyperplasia (BPH)
    Kaczor, M.
    Pawlik, D.
    Becla, L.
    Dardzinski, W.
    Jasinska, A.
    Wojcik, R.
    Walczak, J.
    Nogas, G.
    Cel, M.
    Glogowski, C.
    Zespol-Instytutu, A.
    VALUE IN HEALTH, 2006, 9 (06) : A253 - A254
  • [7] COST-EFFECTIVENESS OF COMBINATION THERAPY FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    Baker, T. M.
    Black, L.
    Bjerklund, Johansen T. E.
    VALUE IN HEALTH, 2009, 12 (07) : A309 - A309
  • [8] Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E258 - E262
  • [9] Cost-effectiveness of Prostate Artery Embolization for Benign Prostatic Hyperplasia
    Gemmete, Joseph J.
    RADIOLOGY, 2023, 309 (03)
  • [10] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345